Birchview Capital, LP’s Bristol-Myers Squibb Co Position
Does Birchview Capital, LP own Bristol-Myers Squibb Co (BMY)? Yes — 306.3K shares worth $19M (+10.57% of its 13F portfolio) as of Q1 2026, up from 302.8K shares the prior filed quarter.
Position Value
$19M
Q1 2026
Shares
306.3K
% of Portfolio
+10.57%
Quarters Held
29
currently held
Position History BMY
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 306.3K | $19M | +10.57% |
| Q4 2025 | 302.8K | $16M | +9.56% |
| Q3 2025 | 316.8K | $14M | +10.79% |
| Q2 2025 | 323.4K | $15M | +14.86% |
| Q1 2025 | 685.2K | $42M | +36.29% |
| Q4 2024 | 685.2K | $39M | +31.59% |
| Q3 2024 | 686.2K | $36M | +30.81% |
| Q2 2024 | 688.2K | $29M | +26.47% |
| Q1 2024 | 703.6K | $38M | +31.15% |
| Q4 2023 | 702.3K | $36M | +28.25% |
| Q3 2023 | 716.3K | $42M | +35.38% |
| Q2 2023 | 728.6K | $47M | +34.92% |
| Q1 2023 | 728.6K | $50,498 | +39.54% |
| Q4 2022 | 727.8K | $52,364 | +36.99% |
| Q3 2022 | 727.8K | $52M | +36.43% |
| Q2 2022 | 727.8K | $56M | +40.76% |
| Q1 2022 | 754.1K | $55M | +39.65% |
| Q4 2021 | 766.1K | $48M | +30.80% |
| Q3 2021 | 796.1K | $47M | +32.05% |
| Q2 2021 | 796.1K | $53M | +31.82% |
| Q1 2021 | 794.2K | $50M | +29.76% |
| Q4 2020 | 794.4K | $49M | +28.39% |
| Q3 2020 | 794.4K | $48M | +32.00% |
| Q2 2020 | 792.4K | $47M | +28.16% |
| Q1 2020 | 785.8K | $44M | +38.85% |
| Q4 2019 | 778.6K | $50M | +36.33% |
| Q3 2019 | 47.0K | $2M | +1.59% |
| Q2 2019 | 44.0K | $2M | +1.21% |
| Q1 2019 | 20.0K | $954,000 | +0.60% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of BMY.